Uso de plasma convaleciente en pacientes COVID-19. Revisión Sistemática.

Abstract

Background: COVID-19 disease is one of the main respiratory tract infections, which most severely affects older adults, immunocompromised and individuals with different risk factors. Different therapeutic support strategies, one of the options being the administration of convalescent plasma, due to its success and effectiveness in different infectious diseases over the years. Objective: To determine the efficacy and safety of the use of convalescent plasma in COVID-19 patients through a systematic review. Methods: It is a qualitative systematic review of randomized, multicenter clinical trials on convalescent plasma use in COVID-19 patients, investigated in Pubmed, Cochrane, Trip Data Base; through the search strategy planned with the PICO system, to later section them using a diagram recommended by the PRISMA guide, in which inclusion and exclusion criteria were applied in order to obtain quality information and perform an appropriate analysis. Results: It was obtained 88 studies were obtained by applying the default search equation. It was selected 10 clinical trials were selected based on the inclusion and exclusion criteria. 10 clinical trials were selected based on inclusion and exclusion criteria, of which 4 have a high quality of evidence, demonstrating a clinical improvement in the first 28 days of 51.9% with the treatment of convalescent plasma compared to 43.1% of the control group. Conclusions: The efficacy of convalescent plasma in COVID-19 patients is reflected in the first days of transmission, however, its effectiveness has not been proven in patients with risk of mortality.